TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive NCI Treatment Division To Recompete $10 Million In Resource Contracts; Board Okays New Projects November 12, 1976
TCL Archive Six More Clinical Trials Proposed For High Priority Status, But Per Case Funds For Them Not Assured June 16, 1989
TCL Archive Science Policy: Increased Cancer Death Rate For Atomic Vets Not Significant, OIM Says October 29, 1999
